Literature DB >> 22627765

Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.

Ann Mullally1, Luke Poveromo, Rebekka K Schneider, Fatima Al-Shahrour, Steven W Lane, Benjamin L Ebert.   

Abstract

In the current model of the pathogenesis of polycythemia vera (PV), the JAK2V617F mutation arises in hematopoietic stem cells (HSCs) that maintain the disease, while erythroid precursor populations expand, resulting in excessive red blood cell production. We examined the role of these specific cell populations using a conditional Jak2V617F knockin murine model. We demonstrate that the most immature long-term (LT) HSCs are solely responsible for initiating and maintaining the disease in vivo and that Jak2V617F mutant LT-HSCs dominate hematopoiesis over time. When we induced Jak2V617F expression in erythropoietin receptor expressing precursor cells, the mice developed elevated hematocrit, expanded erythroid precursors, and suppressed erythropoietin levels. However, the disease phenotype was significantly attenuated compared with mice expressing Jak2V617F in LT-HSCs. In addition to developing a PV phenotype, all mice transplanted with Jak2V617F LT-HSCs underwent myelofibrotic transformation over time. These findings recapitulate the development of post-PV myelofibrosis in human myeloproliferative neoplasms. In aggregate, these results demonstrate the distinct roles of LT-HSCs and erythroid precursors in the pathogenesis of PV.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627765      PMCID: PMC3390954          DOI: 10.1182/blood-2012-01-402396

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment.

Authors:  Sofie Singbrant; Megan R Russell; Tanja Jovic; Brian Liddicoat; David J Izon; Louise E Purton; Natalie A Sims; T John Martin; Vijay G Sankaran; Carl R Walkley
Journal:  Blood       Date:  2011-03-18       Impact factor: 22.113

2.  Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.

Authors:  Takefumi Ishii; Edward Bruno; Ronald Hoffman; Mingjiang Xu
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

3.  Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

Authors:  François Delhommeau; Sabrina Dupont; Carole Tonetti; Aline Massé; Isabelle Godin; Jean-Pierre Le Couedic; Najet Debili; Patrick Saulnier; Nicole Casadevall; William Vainchenker; Stéphane Giraudier
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

4.  Letter: Bone-marrow responses in polycythemia vera.

Authors:  J F Prchal; A A Axelrad
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.

Authors:  Brady L Stein; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2010-10-01       Impact factor: 3.084

Review 7.  Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2012-03       Impact factor: 10.047

8.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

Authors:  Brian J P Huntly; Hirokazu Shigematsu; Kenji Deguchi; Benjamin H Lee; Shinichi Mizuno; Nicky Duclos; Rebecca Rowan; Sonia Amaral; David Curley; Ifor R Williams; Koichi Akashi; D Gary Gilliland
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

9.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

10.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

View more
  36 in total

1.  Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling.

Authors:  Therese Vu; Rebecca Austin; Catherine Paine Kuhn; Claudia Bruedigam; Axia Song; Solene Guignes; Sebastien Jacquelin; Hayley S Ramshaw; Geoffrey R Hill; Angel F Lopez; Steven W Lane
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

2.  Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Authors:  S Hasan; B Cassinat; N Droin; J P Le Couedic; F Favale; B Monte-Mor; C Lacout; M Fontenay; C Dosquet; C Chomienne; E Solary; J L Villeval; N Casadevall; J J Kiladjian; W Vainchenker; I Plo
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

Review 3.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 4.  MicroRNAs in myeloproliferative neoplasms.

Authors:  Huichun Zhan; Christopher Cardozo; Azra Raza
Journal:  Br J Haematol       Date:  2013-02-25       Impact factor: 6.998

5.  Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.

Authors:  T Tsuruta-Kishino; J Koya; K Kataoka; K Narukawa; Y Sumitomo; H Kobayashi; T Sato; M Kurokawa
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

6.  Clonal hematopoiesis: mechanisms driving dominance of stem cell clones.

Authors:  Grant A Challen; Margaret A Goodell
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

7.  JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.

Authors:  Jiahai Shi; Bingbing Yuan; Wenqian Hu; Harvey Lodish
Journal:  Exp Hematol       Date:  2016-07-26       Impact factor: 3.084

8.  JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.

Authors:  Hamza Celik; Won Kyun Koh; Ashley C Kramer; Elizabeth L Ostrander; Cates Mallaney; Daniel A C Fisher; Jingyu Xiang; William C Wilson; Andrew Martens; Alok Kothari; Gregory Fishberger; Eric Tycksen; Darja Karpova; Eric J Duncavage; Youngsook Lee; Stephen T Oh; Grant A Challen
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

9.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

Review 10.  Myeloproliferative neoplasm animal models.

Authors:  Ann Mullally; Steven W Lane; Kristina Brumme; Benjamin L Ebert
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.